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Historical Vignette
Endovascular aortic aneurysm repair (EVAR) has drastically altered the treatment landscape and replaced open surgical repair as the primary treatment modality for majority of abdominal aortic aneurysms (AAAs) in large parts of the world. Since its inception in the early 1990s as an experimental alternative to patients unfit for open surgical repair, it has today caused a paradigm shift in the management of most uncomplicated AAAs with rapidly widening indications in the treatment of anatomically complicated pararenal and suprarenal AAAs. [1] EVAR was introduced to most of the world by the work of Parodi et al. published in 1991 in the Annals of Vascular Surgery. [2] This introduced a radical change at a time when open surgical repair was well established as a robust procedure to treat most AAAs, and most vascular surgeons had not acquired the skill sets for endovascular intervention. The lack of complete understanding of the anatomic complexities, disease progression, and sophisticated imaging added to the initial doubts and dismissive resistance to its widespread use in the early phase.
beHinD THe iROn cURTAin
Unknown to most in the English-speaking world, the earliest attempts at design and successful aortic endografting occurred in Ukraine in the erstwhile USSR. Tragically, the extent and path-breaking quality of their work remained hidden in the English language publications due to the existing sociopolitical circumstances.
Prof. Nicolai Leontyevich Volodos (May 15, 1934,-April 3, 2016) was the master innovator heading the team at Kharkov Research Institute of General and Emergency Surgery (USSR). Although he was well known to the international surgical community, the details of his pioneering insights and the meticulous detail of his research work in aortic endografting remained underexposed to most of the world till recent years.
Prof. Volodos [ Figure 1 ] graduated from Odessa Medical School in Ukraine. He trained in cardiovascular surgery and then defended his PhD thesis at Kharkov Medical Postgraduate Institute in 1971. He developed an early interest in self-expanding vascular grafts with the ability for self-fixation within the vessel lumen. Inspired by the work of Charles Dotter and with the help from scientists who were familiar with use of materials in space and defense industry, he developed the first model of a self-expanding stent in the form of a radial cylindrical tube of stainless steel wires with a Z-shaped lateral frame. This frame, when inserted into a vascular graft, was able to fix the graft in the vessel lumen from within, and thus, the first self-expanding covered stent was produced. Further refinements in stent design and creation of new delivery systems that could be used to deploy the device from the femoral arteries were developed, and the first USSR patent was obtained in May 1984. Extensive animal experiments then prepared the device for human use. [3, 4] complications in a couple of patients who underwent open repair of AAA spurred the interest to develop a catheter-based solution. Preliminary work on device design was done at the Cleveland Clinic after which he returned to Argentina. In collaboration with Dr. Palmaz, and bioengineer Hector Barone, Dr. Parodi used the extra-large Palmaz stent to design devices up to 30 mm in diameter. This was followed by extensive experiments in dogs in the late 1980s, most of it without any external funding.
The first successful EVAR case on a human was done in September 1990. The patient had a large AAA causing back pain and had severe chronic obstructive pulmonary disease, making him unfit for an open repair. The first device was an aortic stent graft and had a graft designed with expandable ends, the extra-large Palmaz stent, a Teflon sheath with a valve, a wire, and a valvuloplasty balloon. The first case was done along with Dr. Palmaz and Hector Barone. The procedure was successful initially, but the initial patients started developing distal aortic endoleaks after a few months. This was tackled with an aorto-uni-iliac device extension with occlusion of the contralateral common iliac artery and a femoro-femoral bypass. [6, 7] Dr. Parodi's results were received with great skepticism, and the first cases were published only in November 1991. Over the next couple of years, Dr. Parodi worked with teams around different countries and introduced EVAR to the rest of the world. The first EVAR in Europe was performed as a live case at a meeting in Nancy, France, by Dr. Parodi, Claude Mialhe, Claude Amicabile, and Claudio Schonholz in October 1992. This was followed by the first EVAR in the US with Frank Veith, Michael Marin, Jacob Cynamon, and Claudio Schonholz in New York in November 1992 and at the Royal Perth Endovascular Unit in Australia led by Michael Lawrence-Brown. [8] EVAR then went on to spread rapidly among different continents and across different specialties with selfless and extensive collaboration, resulting in advancements in device design and delivery systems. Bifurcated devices were developed and eventually became standard practice. Pioneering work by Timothy Chuter and Roy Greenberg made it possible to extend EVAR into the suprarenal and thoracic abdominal aortic segment.
The EVAR procedure that is done today is vastly different from how it all started and it is difficult to even imagine how the initial devices coupled with the primitive imaging adjuncts worked successfully. That EVAR is today established as the primary treatment modality for most uncomplicated AAAs is in itself a tribute to the sheer determination, vision, and ingenuity of the pioneers of aortic endografting.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest. Dr. Juan C Parodi [ Figure 2 ] was born in Argentina. He started his journey of innovation in aortic endografting, while he was a vascular fellow at the Cleveland Clinic. Successive 
